OS Therapies, Inc. (AMEX:OSTX) Aligned With MHRA/EMA on CMAA; Phase 3 To Start in Q4 2026
OS Therapies achieved full alignment with the UK MHRA and EU EMA on its Conditional Marketing Authorisation plans and Phase 3 design for OST-HER2, expects CMAA filing in coming weeks, and intends to start the confirmatory Phase 3 in Q4 2026.Material DetailsContext by AI AnalystThis is a mid-stage r…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.